Cisplatin Resistance: From DNA Damage to Ferroptosis

Introduction: resistance is more than failed DNA damage

Cisplatin is a platinum-based anticancer compound used to study how tumor cells respond to DNA damage. Its established activity provides a clear experimental starting point: after entering cells, it forms platinum–DNA adducts, disrupts replication and transcription, and can lead to cell-cycle arrest and cell death. Yet a DNA-damaging treatment does not produce the same outcome in every cell. Tumors may limit drug accumulation, repair or tolerate DNA lesions, or shift signaling so that damaged cells avoid death.

This difference between damage and fate is central to chemotherapy resistance studies. A cell can accumulate evidence of injury without undergoing apoptosis, while other forms of regulated cell death may contribute to the response. A recent lung adenocarcinoma study offers a useful example: rather than treating cisplatin response solely as a DNA-damage problem, it investigated whether ferroptosis could help explain how resistant cells respond to treatment. That perspective complements, rather than replaces, the conventional DNA-crosslinking model.

For researchers selecting a compound for these experiments, Cisplatin (A8321) is described by APExBIO as a research compound for cancer models, including cell-based studies and tumor xenografts. Its handling characteristics matter for interpreting results: it is insoluble in water and ethanol, soluble in DMF at concentrations of at least 12.5 mg/mL, and its solutions are unstable. The product information recommends storing the powder at 4°C protected from light, preparing solutions fresh, and avoiding DMSO, which can inactivate cisplatin.

From platinum–DNA adducts to a cellular decision

DNA lesions initiate—but do not dictate—the response

Inside a cell, cisplatin forms covalent adducts at DNA bases, particularly guanine. The resulting lesions include frequent intrastrand crosslinks and less common but consequential interstrand crosslinks. These distort the DNA template and obstruct polymerases, challenging both replication and transcription. The cell’s response depends on lesion burden, repair capacity, replication state, and the signaling networks that govern arrest, survival, and death.

When damage is sufficiently severe, p53-associated signaling and caspase-dependent apoptosis can contribute to cell elimination. Caspase-9 and caspase-3 are commonly examined as components of this apoptotic response. Cisplatin can also increase reactive oxygen species (ROS), contributing to oxidative stress and lipid damage. These events can intersect with DNA damage signaling, but they should not be collapsed into one mechanism: DNA adduct formation, oxidative changes, apoptosis, and ferroptosis are distinct measurements with potentially overlapping causes.

That distinction is practically important. A viability decrease alone does not show whether a treatment caused apoptosis, ferroptosis, or another outcome. Likewise, an increase in ROS does not establish that lipid-peroxidation-driven ferroptosis is responsible for cell loss. A useful experiment therefore pairs a response measurement with mechanism-oriented readouts and asks whether those readouts change together under the same conditions.

Why resistant cells can remain viable after treatment

Cisplatin resistance can arise through multiple routes, including altered drug handling, enhanced lesion repair or tolerance, and changes in pro-survival or cell-death pathways. These possibilities can coexist. An apparent reduction in sensitivity should therefore be defined operationally—for example, by comparing dose–response behavior in a parental line and a resistant derivative under matched assay conditions—rather than attributed to a single pathway based on viability data alone.

This framing also helps separate two research questions. One asks whether a cell is less responsive to cisplatin. The other asks why. The first may be addressed with a carefully controlled viability assay; the second usually requires additional endpoints that test DNA damage, redox state, cell-death signaling, or candidate resistance mechanisms.

What the ferroptosis study adds

A resistant lung adenocarcinoma model tests a different vulnerability

In the study by Li and colleagues, investigators established cisplatin-resistant A549/DDP lung adenocarcinoma cells through repeated exposure of parental A549 cells to increasing cisplatin concentrations. They compared cellular responses using CCK-8 viability measurements and examined ferroptosis-associated features, including malondialdehyde (MDA), glutathione (GSH), ferrous iron (Fe²⁺), cytosolic ROS, and lipid ROS. Western blotting was used to assess PI3K/AKT pathway proteins and several proteins related to p53 signaling and ferroptosis regulation.

The authors reported that dihydroisotanshinone I (DT) inhibited parental and resistant cells in a time- and concentration-dependent manner, and that DT combined with cisplatin showed a synergistic inhibitory effect in A549/DDP cells. Their results supported a role for ferroptosis in the resistant-cell response to DT and the combination. The paper further proposed that DT enhanced cisplatin sensitivity through regulation involving the PI3K/MDM2/p53 pathway. These are findings from the reported cell model; they do not establish that the same combination or pathway will operate in every tumor type.

The practical innovation: measure the route to cell loss

The study’s most useful contribution for assay planning is its focus on cell-death phenotype in a resistant background. A conventional cisplatin viability curve can reveal that cells are less sensitive, but it cannot identify whether another compound restores response by changing ferroptosis-related processes, apoptotic signaling, or a separate mechanism. By combining viability with measurements of lipid ROS, MDA, GSH, Fe²⁺, and protein expression, the investigators built a broader evidence set around the proposed ferroptosis response.

This does not make any single marker definitive. For example, ROS and MDA are informative indicators of oxidative or lipid damage but are not, on their own, proof that ferroptosis caused a viability change. Protein abundance also does not necessarily report pathway activity. The value lies in evaluating a pattern of results across complementary assays and interpreting it against the study model and treatment conditions.

For practical decisions, the paper suggests a useful sequence: first establish the resistant phenotype; then measure treatment response; then add mechanistically relevant endpoints that distinguish lipid oxidation and antioxidant status from apoptosis. If the claim is that a treatment reverses resistance through ferroptosis, the evidence should support both parts of that statement—the change in cisplatin response and the proposed cell-death mechanism. The study provides a rationale for that design, not a universal assay recipe or a clinical treatment recommendation.

Designing experiments that distinguish response from mechanism

Start with matched comparisons

For a resistance experiment, compare parental and resistant cells using matched culture conditions, treatment timing, and vehicle exposure. Establish a cisplatin dose–response in each population before interpreting a candidate sensitizer. Include untreated and vehicle controls, and consider testing the candidate compound alone alongside the combination: otherwise, a combination-associated decrease in viability may simply reflect the candidate’s independent toxicity.

When evaluating a combination, use a prespecified approach to characterize interaction rather than describing a lower viability value as synergy by default. The study reports a synergistic effect in A549/DDP cells, but the supplied findings do not provide a dosing schedule or numerical interaction metric to reproduce. Researchers should therefore select and report an appropriate combination-analysis method for their own design and avoid inferring synergy from a single pair of treatment conditions.

Pair viability with orthogonal endpoints

An apoptosis assay can help test whether the expected apoptotic response accompanies cisplatin exposure, while caspase-related measurements may provide additional pathway evidence. For a ferroptosis-oriented question, lipid ROS, MDA, GSH, and Fe²⁺ can help characterize relevant changes. Include appropriate assay controls and interpret results together: an isolated ROS increase, for example, is not sufficient to assign a specific death mechanism. Where feasible, confirm that the selected readouts are compatible with the cell type, exposure interval, and detection method.

Researchers should also distinguish pathway association from causation. Changes in PI3K, AKT, MDM2, p53, GPX4, or SLC7A11 expression can help prioritize hypotheses, but protein-expression data alone do not show that a pathway is necessary for the observed response. Mechanistic claims are stronger when supported by suitable perturbation and rescue experiments, in addition to phenotypic measurements.

Protocol Parameters

• Compound handling: The product information describes cisplatin as insoluble in water and ethanol and soluble in DMF at concentrations of at least 12.5 mg/mL. Prepare working solutions fresh, protect powder from light at 4°C, and avoid DMSO; these are product-specific handling details, not a cell-treatment dose recommendation.
• Resistance comparison: Compare a parental population with a resistant derivative under matched conditions. The reference study generated A549/DDP cells by repeated exposure to increasing cisplatin concentrations; it does not provide, in the findings summarized here, a transferable selection schedule.
• Combination testing: Test cisplatin and the candidate agent separately as well as together, with vehicle controls. Determine dose and exposure duration empirically for the selected model rather than importing unreported values from the reference study.
• Mechanism readouts: Pair a viability endpoint with orthogonal measurements selected for the hypothesis, such as lipid ROS and redox-associated markers for a ferroptosis question or caspase-related endpoints for apoptosis. Treat these as workflow recommendations; validate assay performance in the chosen cells.
• In vivo extension: Tumor growth inhibition in xenograft models can extend cell-based findings, but a cell-culture result alone does not predict xenograft efficacy. Establish an appropriate study design and evaluate tolerability and tumor response separately.

How this article differs from existing Cisplatin resources

The existing article Cisplatin: Atomic Mechanisms and DNA Crosslinking focuses on the chemical basis of DNA adduct formation and cisplatin’s role as a benchmark compound. This article uses that mechanism as a starting point, then shifts the emphasis to a different question: how ferroptosis-associated measurements may help explain response in a resistant lung adenocarcinoma model.

Similarly, Cisplatin: Applied Workflows and Optimization in Cancer Research addresses experimental workflow considerations. Here, handling and assay design are included only to support interpretation of the resistance study. The central contribution is not a general protocol catalogue, but a framework for distinguishing reduced viability from evidence about the biological route to cell death.

Limitations and interpretation

The reference findings are based on cell models, including A549/DDP, and should not be treated as evidence that DT reverses cisplatin resistance in patients. The reported association between pathway changes and ferroptosis also needs to be interpreted within the methods and conditions used in that study. Different tumor backgrounds, resistance mechanisms, exposure schedules, or assay platforms may produce different results. In particular, results from one lung adenocarcinoma model cannot establish a general rule for ovarian, lung, or other cancers.

These limitations do not diminish the study’s experimental value. They define where its findings are most useful: as a rationale for testing cell-death mechanisms alongside standard drug-response measurements, and for asking whether a candidate sensitizer changes both the phenotype and the proposed mechanism in a given model.

Conclusion: use Cisplatin to ask a sharper resistance question

Cisplatin remains a valuable tool for studying DNA damage, apoptosis, oxidative stress, and chemotherapy resistance. The lung adenocarcinoma study adds a distinct perspective by connecting a resistant-cell model with ferroptosis-associated measurements and proposed PI3K/MDM2/p53 regulation. For researchers, the key lesson is methodological: a viability change identifies a response, while complementary, hypothesis-matched assays help evaluate how that response may arise.

When planning cancer research with CDDP, separate compound handling from biological interpretation, establish resistance under controlled comparisons, and avoid assigning a death mechanism from a single marker. This approach makes findings more interpretable and gives follow-up studies a clearer basis for testing whether the ferroptosis connection observed in A549/DDP cells extends to other models.